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Introduction
The main treatment of Hodgkin lymphoma consists 
of ABVD (doxorubicin, bleomycin, vinblastine (Vb) and 
dacarbazine) regimen and/or involved field radiotherapy 
(IFRT) (Canellos et al., 1992). The number of chemotherapy 
cycles mainly depends on stage and unfavorable risk 
factors in early stage (Chakrabarti et al., 2010). The ABVD 
regimen has become the standard chemotherapy regimen 
in Hodgkin Lymphoma (HL) after it was shown that 
ABVD seemed to better than MOPP (mechlorethamine, 
vincristine, procarbazine and prednisone) and equivalent 
to MOPP/ABVD with less toxicity (Bonadonna et al., 
1975; Canellos et al., 1992). The BEACOPP (bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, 
procarbazine, prednisone) regimen is another investigated 
one in advanced stage HL. Viviani et al reported better 
initial tumor control with BEACOPP in advanced stage, 
but it had similar long-term outcomes with ABVD (Viviani 
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Abstract
 Background: ABVD (doxorubicin, bleomycin, vinblastine (Vb) and dacarbazine) is the standard regimen in 
Hodgkin’s lymphoma (HL).Vincristine (O) is a mitotic spindle agent like Vb. We aimed to evaluate the efficacy 
and safety of O as a part of ABOD in HL. Materials and Methods: Patients who had ABOD were enrolled. Stage 
I-II HL were evaluated for unfavorable risk factors according to NCCN. National Cancer Institute Common 
Toxicity Criteria was used for toxicity. Results: Seventy-nine HL patients in our center between 2003 and 2007 
were evaluated retrospectively. Median follow-up was 54 months. Most of the patients were male in their third 
decade. Median ABOD cycles were 6 (2-8). Primary refractory disease rate was 17.7% whereas it was 5.1% for 
early relapse and 5.1% for late relapse disease. Response rates were as 82.3% for complete response, 11.4% 
for partial response, 5.1% for stable disease and 1.3% for progressive disease. Half of relapsed patients had 
autologous stem cell transplantation. Estimated 5-year failure-free survival was 71% and significantly longer 
in early stage patients without risk factors, bulky disease or radiotherapy (RT) (p=0.05, p<0.0001, p=0.02; 
respectively). Estimated 5-year overall survival was 74% and significantly longer in those who had no RT 
(p=0.001). Dose modification rate was 5.1% and chemotherapy delay rate was 19%. There were no toxicity-
related deaths. Conclusions: ABOD seems to be effective with managable toxicity in HL, even in those with poor 
prognostic factors. 
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et al., 2011). Vincristine (O) is a vinca alkaloid which 
depolymerizes microtubules leading mitotic arrest, like 
Vb. It has been used as a part of alternating regimen of 
PABIOE (doxorubicin, bleomycin, vincristine, etoposide) 
with ChlVPP (chlorambucil, vinblastine, procarbazine, 
prednisone) besides MOPP and BEACOPP in HL 
(Cullen et al., 1994; Hancock et al., 2001). However, it 
is not a standard component of ABVD. We had to use 
vincristine instead of Vb with doxorubicin, bleomycin and 
dacarbazine (ABOD) in HL since we could not provide 
Vb in those years, taking into account our experience 
with vincristine in MOPP and BEACOPP regimens in HL 
(Bonadonna et al., 1975; Engert et al., 2009; Fatima et al., 
2011). In this study, we aimed to evaluate the efficacy and 
safety of vincristine as a part of ABOD in HL. 
Materials and Methods
We enrolled only classic Hodgkin lymphoma patients 
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who had ABOD to the study. Risk classification in the 
patients with early stage (stage I-II HL) was performed 
according to National Cancer Comprehensive Network 
(NCCN). The patients were stratified as early stage with 
unfavorable risk factors, early stage without unfavorable 
risk factors and advanced stage. Bulky disease was defined 
as large mediastinal lymphadenopathy greater than one 
third of the thoracic diameter at T5 or T6 vertebrae or mass 
more than 5-10 cm in width. The patients were evaluated 
for clinicopathological characteristics, response rates, 
failure-free survival and overall survival (OS) besides 
chemotherapy efficacy and toxicity. National Cancer 
Institute (NCI) Common Toxicity Criteria was used for 
toxicity. Response Evaluation Criteria in Solid Tumors 
(RECIST) version 1.0 was used for response evaluation. 
The patients with no response to the primary treatment 
were accepted as primary refractory patients. Relapse 
in the first six months of remission was defined as early 
relapse whereas relapse after six months was defined as 
late relapse. The intervals between the date of diagnosis 
and the date of progression from partial remission or the 
date of relapse from a complete remission were defined as 
failure-free survival (FFS) while the interval between the 
date of diagnosis and the date of death or last known alive 
was defined as overall survival (OS). Both of regression 
and stabilization of the disease were defined as clinical 
benefit. 
Statistics
Statistical analyses was performed by using SPSS for 
Windows version 18.0 (SPSS, Chicago, IL). Tumors with 
missing values were omitted from the analyses. The data 
were retrospectively analyzed for FFS and OS according 
to the risk groups. Kaplan-Meier survival analysis was 
carried out for FFS and OS. The log-rank test was used 
to examine the statistical significance of the differences 
observed between the groups. Two-sided P values of <0.05 
were considered statistically significant.
Results 
Seventy nine HL patients admitted to Medical 
Oncology Department of Ankara Numune Training and 
Reseach Hospital between December 2003 and November 
2007 were evaluated retrospectively. Median follow-up 
was 54 months. Most of the patients were male in the 
third decade. Half of the patients (54.5%) had nodular 
sclerosing-HL. Seventy six percent of the patients had 
either unfavorable early stage or advanced stage disease. 
Most (60%) of the patients had B symptoms. The most 
common B symptoms was weight loss (51%). Bulky 
disease occured in 27% of the patients at diagnosis. 
Treatment efficacy
Median ABOD cycle was 6 (range: 2-8).Response 
rates were as 82.3% for complete response (CR), 11.4% 
for partial response, 5.1% for stable disease and 1.3% for 
progressive disease. One third of the patients had primary 
refractory or relapsed disease. Primary refractory disease 
rate was 17.7% whereas it was 5.1% for early relapse 
and 5.1% for late relapse. Half of relapsed patients had 
autologous stem cell transplantation (ASCT). Most 
common preferred salvage chemotherapy regimen before 
ASCT was ICE (ifosfamide, carboplatin and etoposide) 
with a rate of 75%. Sixty percent of the patients had 
IFRT. Median FFS and OS were not reached, but 5-year 
FFS was 71% while 5-year OS was 74% (Figures 1,2). 
Estimated 5-year FFS was significantly longer in those 
with low risk early stage, bulky disease or radiotherapy 
Figure 1. Failure Free Survival (FFS) of the ABOD 
Group
Figure 2. Overall Survival of ABOD Patients
Table 1. The Survival Rates of the Study Population 
According to the Patient Characteristics
Patient  5 yrs  p value 5 yrs p value
Characteristics FFS (%)  OS (%) 
Sex Male 67 0.13 79 0,60
 Female 78  80 
Stage    
 Early stage  favorable 94  94 
 Early stage unfavorable 61 0.05 85 0,07
 Advanced stage 64  66 
ECOG-Performance Status (n)    
 0-1 74 0.18 76 0,11
 2-4 50  50 
Histology    
 Nodular sclerosing-HL 66  79 
 Mixed cellularity-HL 75 0.86 67 0,36
 Lymphocyte rich-HL 72  100 
 Lymphocyte depleted-HL  50  100 
LDH High 65 0.18 84 0,60
 Normal 80  74 
Bulky disease Yes 42 0.0001 65 0,14
 No 83  86 
Radiotherapy Yes 82 0.02 94 0,001
 No 54  60 
B symptoms Yes 68 0.57 76 0,20
 No 75  87 
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(RT) in univariate analysis (p=0.05, p<0.0001, p=0.02; 
respectively). Estimated 5-year OS was significantly 
longer in those who had no RT (p=0.001). The early 
stage HL patients without risk factors had also longer 
OS, however the difference was not statistical significant 
(p=0.07). The patient characteristics which might affect 
survival are listed in Table 1.
Toxicity
The toxicity rates are summarized in Table 2. Grade 
3-4 toxicity rates were as 12.6% for neutropenia, 3.8% 
for anemia, 2.5% for febrile neutropenia and 1.3% for 
thrombocytopenia or neuropathy or nephrotoxicity. Dose 
modification was applied to 5.1% of the patients whereas 
chemotherapy was delayed in 19% of the patients. There 
was no toxic death. 
Discussion
Treatment of HL depends on stage and risk factors. 
ABVD and/or IFRT are the standard modalities in HL 
(Canellos et al., 1992; Meyer et al., 2005; Meyer et al., 
2012). The Stanford V regimen is also an alternative 
regimen for early stage without poor prognostic factors 
while the results of escalated BEACOPP regimen 
in unfavorable early stage and advanced stage are 
encouraging (Advani et al., 2013). However, escalated 
BEACOPP has high toxicity rates such as more than 80% 
grade 3/4 hematological toxicity and 3% toxic death, even 
in younger patients (<60 years) with better performance 
status (Diehl et al., 1998; Viviani et al., 2011). 
Vincristine was used as a part of ABOD in our study 
taking into account the experience with other regimens 
like MOPP and BEACOPP. We had to use it because 
of Vb shortness as mentioned before. We preferred to 
compare our ABOD results with historical ABVD control 
by Canellos, since it is the standard chemotherapy regimen 
in HL (Table 2-3) (Canellos et al., 1992). Our patients 
had male predominance in the third decade like historical 
ABVD control study (Canellos et al., 1992). The response 
rates were comparable despite lower rate of patients with 
better performance status in our study [82.3% versus 90% 
for ECOG-PS (0-1)]. In addition, approximately 8 % of 
our patients had poor performance status (ECOG-PS: 3-4) 
though there was no patient with poor PS in historical 
ABVD control study. The response rates similar in both 
studies. Five-year OS was also similar whereas 5-year 
FFS seems to be quite higher in our patients (73% versus 
74%, 71% versus 64%, respectively). 
The severe toxicity profile did not differ from ABVD 
historical control (Table IV). Severe neutropenia was 
lower (12.6% versus 18%) while febrile neutropenia was 
similar (2.5% versus 2%) in comparison of ABOD and 
ABVD regimens (Canellos et al., 1992). Our patients had 
more grade 3/4 peripheral neuropathy (1.3% versus 1%) 
although vincristine and Vb are members of the same 
family. Inspite of similar mechanism of vinca alkaloids, 
Vb seems to have more intracellular retention than 
vincristine (Abu-Khalaf MM, 2011). It might lead rarely 
different toxicity profiles like hematologic side effects. 
Neutropenia is a dose-limiting side effect with Vb while 
it is rare with vincristine. We consider that this might have 
contributed to less neutropenia in our patients. There was 
no toxic death in our study. However, we consider that our 
study might have also some limitations while evaluating 
toxicity profile since it is retrospective. 
In conclusion, high clinical benefit with managable 
toxicity with ABOD regimen seems to be encouraging in 
HL. We consider that in shortage of vinblastine, vincristine 
seems to be a reliable substitute for Vb. However, further 
prospective trials with large number of patients are needed 
for ABOD in HL.
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Table 2. ABOD Related Toxicity Rates
Toxicity  Grade 1-2 n (%) Grade 3-4 n (%)
 Anemia 40   (50.6) 3   (3.8)
 Neutropenia  19   (24.1) 10 (12.6)
 Thrombocytopenia  3     (3.8) 1   (1.3)
 Hepatotoxicity  3     (3.8) 0   (0)
 Renal toxicity  6     (7.6) 1   (1.3)
 Peripheral neuropaty  8   (10.1) 1   (1.3)
 Total 79 (100) 16 (20)
Table 3. Response and Severe Toxicity Rates with 
Comparison of ABOD and Historical ABVD Control
  ABOD ABVD
   (n=79) %  (n=115) %
ECOG-PS 0-1 82.3 90
 2 10.1 10
 3-4 7.6 0
Response rates (%) Complete response 82.3 82
 Partial response 11.4 13
 Stable disease 5.1 2
 Clinical benefit (%) 98.8 97
Severe toxicity rates (%) Anemia 3.8 5
 Thrombocytopenia 1.3 2
 Neutropenia 12.6 18
 Febrile neutropenia 2.5 2
 Peripheral neuropathy 1.3 1
Total  21.5 28
 5 yea-FFS (%) 71 61
 5 year-OS (%) 74 73
*ECOG: Eastern Cooperative Oncology Group,  FFS: Failure-Free Survival, OS: Overall 
Survival, PS: performance score
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